VentasVTREarnings & Financial Report
Ventas is a leading real estate investment trust specializing in healthcare-related real estate assets. Its portfolio includes senior housing, medical offices, life science research facilities and rehabilitation centers, operating mainly across North America and the UK, serving healthcare operators and life science groups.
VTR Q1 FY2026 Key Financial Metrics
Revenue
$1.7B
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$59.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
3.6%
YoY Growth
22.0%
EPS
$0.57
Ventas Q1 FY2026 Financial Summary
Ventas reported revenue of $1.7B (up 22.0% YoY) for Q1 FY2026, with a net profit of $59.0M (up 19.0% YoY) (3.6% margin).
Key Financial Metrics
| Total Revenue | $1.7B |
|---|---|
| Net Profit | $59.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Ventas Q1 FY2026 revenue of $1.7B breaks down across 4 segments, led by Resident fees and services at $1.3B (78.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Resident fees and services | $1.3B | 78.0% |
| Outpatient medical and research portfolio | $230.1M | 13.9% |
| Triple-net leased properties | $123.1M | 7.4% |
| Third-party capital management revenues | $4.4M | 0.3% |
Ventas Annual Revenue by Year
Ventas annual revenue history includes year-by-year totals (for example, 2025 revenue was $5.8B).
Ventas Quarterly Revenue & Net Profit History
Ventas results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $1.7B | +22.0% | $59.0M | 3.6% |
| Q4 FY2025 | $1.6B | +21.7% | $73.0M | 4.7% |
| Q3 FY2025 | $1.5B | +20.4% | $68.7M | 4.6% |
| Q2 FY2025 | $1.4B | +18.3% | $71.5M | 5.0% |
| Q1 FY2025 | $1.4B | +13.2% | $48.4M | 3.6% |
| Q4 FY2024 | $1.3B | +10.5% | $58.7M | 4.6% |
| Q3 FY2024 | $1.2B | +7.5% | $21.0M | 1.7% |
| Q2 FY2024 | $1.2B | +8.6% | $21.2M | 1.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.20B | $1.24B | $1.29B | $1.36B | $1.42B | $1.49B | $1.57B | $1.66B |
| YoY Growth | 8.6% | 7.5% | 10.5% | 13.2% | 18.3% | 20.4% | 21.7% | 22.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $24.53B | $25.35B | $26.19B | $26.03B | $26.47B | $26.93B | $27.59B | $27.69B |
| Liabilities | $14.55B | $15.19B | $15.05B | $14.17B | $14.55B | $14.15B | $14.63B | $14.11B |
| Equity | $9.62B | $9.76B | $10.77B | $11.47B | $11.53B | $12.36B | $12.53B | $13.18B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $335.9M | $353.7M | $373.6M | $321.1M | $475.3M | $378.6M | $471.7M |